Research Topics
Species | Hans Joachim StemmlerSummaryAffiliation: University of Munich Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Radioembolization in patients with hepatic metastases from breast cancerTobias F Jakobs
Department of Radiology, Ludwig Maximilians University of Munich, Campus Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
J Vasc Interv Radiol 19:683-90. 2008....- Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case reportHans Joachim Stemmler
Medical Department III, Ludwig Maximilians University of Munich, Klinikum Grosshadern, Munich, Germany
Anticancer Drugs 19:832-6. 2008..This case report gives details regarding the clinical course of a breast cancer patient who received intrathecal trastuzumab and methotrexate via lumbar puncture for meningeal carcinomatosis of HER2-overexpressing MBC... 
Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumabHans Joachim Stemmler
Medizinische Klinik III, Hämatologie Onkologie, Institut fur Klinische Chemie, LMU Munchen, Klinikum Grosshadern, Germany
Onkologie 28:95-7. 2005..In general, HER2 status in a primary lesion predicts the status of metastases, so that biopsy of metastatic lesions appears unnecessary...
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancerH J Stemmler
Med Department III, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
Br J Cancer 104:1071-8. 2011..Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory...- Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancerHans Joachim Stemmler
Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
Oncology 79:204-10. 2010..The present trial was initiated to compare the toxicity and efficacy of weekly docetaxel versus its standard 3-weekly application in combination with doxorubicin... - Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancerHans Joachim Stemmler
Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilian University of Munich, Munich, Germany
Oncology 79:197-203. 2010..The present trial was initiated to randomly compare the toxicity and efficacy of weekly docetaxel versus its standard 3-weekly application... - Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challengeHans Joachim Stemmler
Department of Haematology and Oncology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
Oncologist 13:739-50. 2008.... - [Oncology 2008]H-J Stemmler
Medizinische Klinik und Poliklinik III, , Standort Grosshadern, Marchioninistrasse 15,
Dtsch Med Wochenschr 133:1395-9. 2008 - Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierHans Joachim Stemmler
Medical Department III, Ludwig Maximilians University of Munich, Clinic Grosshadern, Munich, Germany
Anticancer Drugs 18:23-8. 2007.... - [Lymphadenopathy and constitutional symptoms. Progress of a low-grade follicular lymphoma?]H J Stemmler
Medizinische Klinik III, Klinikum Grosshadern der LMU München
Internist (Berl) 47:528-32. 2006..Within a few days of cyclophosphamide and prednisone treatment the clinical presentation improved and imaging studies detected regression of all manifestations during follow-up... - Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancerH J Stemmler
Department of Internal Medicine III, Ludwig Maximilians University of Munich, Klinikum Grosshadern, D 81377 Munich, Germany
Oncol Rep 15:1373-7. 2006.... - High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II studyH J Stemmler
Department of Medicine III, Klinikum Grosshadern, University of Munich, Germany
Clin Oncol (R Coll Radiol) 17:630-5. 2005..This multicentre phase II study aimed to evaluate the efficacy and tolerability of gemcitabine and cisplatin plus trastuzumab in previously treated patients with metastatic breast cancer (MBC)... - Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancerH J Stemmler
Medical Department III, University of Munich, Grosshadern, Germany
Breast 15:219-25. 2006..Since one third of HER2 overexpressing patients with MBC developed BM despite effective trastuzumab treatment, new treatment strategies and closer surveillance may be warranted for these patients... - Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)Hans Joachim Stemmler
Medical Department III, University Hospital of Munich, Grosshadern, Germany
Onkologie 28:582-6. 2005..The study specifically focussed on the influence of the continuation of trastuzumab-based treatment despite tumor progression on survival... - Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case reportH J Stemmler
Medizinische Klinik III bInstitut für Klinische Radiologie, University Hospital of Munich, Klinikum Grosshadern, Munich, Germany
Anticancer Drugs 16:747-9. 2005..Within 4 months of treatment there were no side-effects such as skin rash or any other systemic toxicity. Gefitinib may therefore have a role in the treatment of brain metastases from NSCLC... - Lasting remission following multimodal treatment in a patient with metastatic breast cancerH J Stemmler
Department of Hematology Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
Anticancer Drugs 16:1135-7. 2005..Further investigation of this approach is indicated in a subgroup of patients with oligometastatic breast cancer... - Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot studyH J Stemmler
Department of Hematology Oncology, University of Munich, Germany
Anticancer Res 25:3047-54. 2005.... - Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiographySandra Geiger
Medical Department III, Ludwig Maximilians University of Munich, Germany
Onkologie 35:241-6. 2012.... - UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Christoph Schulz
Department of Haematology, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
Anticancer Drugs 20:867-79. 2009.... - Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastasesTobias F Jakobs
Department of Radiology, Ludwig Maximilians University of Munich, Munich, Germany
J Vasc Interv Radiol 19:1187-95. 2008..To present data for radioembolization with yttrium-90 ((90)Y) resin microspheres in patients with colorectal cancer liver metastases in whom currently available therapies had failed... - Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS statusDominik P Modest
Medical Department III, Hospital of the University, University of Munich, Germany
Anticancer Drugs 22:913-8. 2011..Compared with KRAS codon 12 mutations, codon 13-mutated mCRC presents as a more aggressive disease frequently associated with local and distant metastases at first diagnosis... - Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005Sandra Geiger
Medical Department III, Ludwig Maximilians University of Munich, Campus Grosshadern, Germany
Anticancer Drugs 22:933-9. 2011.... - Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?Sandra Geiger
Medical Department III, Ludwig Maximilians University of Munich, Germany
Anticancer Drugs 21:799-804. 2010..This review will discuss the extent to which individualized adjuvant treatment can be provided... - Mechanical ventilation with positive end-expiratory pressure in critically ill patients: comparison of CW-Doppler ultrasound cardiac output monitoring (USCOM) and thermodilution (PiCCO)Sophia Horster
Medical Dept II, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
Acta Cardiol 67:177-85. 2012.... - UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancerChristoph Schulz
Department of Haematology and Oncology, Ludwig Maximilians University of Munich, Campus Grosshadern, Marchioninistr 15, Munich 81377, Germany
World J Gastroenterol 15:5058-66. 2009.... - Cardiac Output Measurements in Septic Patients: Comparing the Accuracy of USCOM to PiCCOSophia Horster
Medical Department II, Ludwig Maximilian University of Munich, Campus Großhadern, Marchioninistrase 15, 81377 Munich, Germany
Crit Care Res Pract 2012:270631. 2012..USCOM does reliably represent CO values as compared to the reference technique based on thermodilution (PiCCO). It seems to be appropriate in situations where CO measurements are most pertinent to patient management... - Anticancer therapy induced cardiotoxicity: review of the literatureSandra Geiger
Medical Department III, Haematology and Oncology, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
Anticancer Drugs 21:578-90. 2010..The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study... - CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancerTobias F Jakobs
Department of Radiology, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
Cardiovasc Intervent Radiol 32:38-46. 2009..Solitary bone metastases did not negatively affect survival probability after RF ablation... - Prognostic parameters and risk stratification in intensive care patients with severe liver diseasesSebastian Lehner
Department of Internal Medicine II, Department of Nuclear Medicine Ludwig Maximilians University Campus Großhadern, Marchioninistrase 15, 81377 Munich, Germany
J Gastrointestin Liver Dis 19:399-404. 2010..Thus, it is necessary to identify clinical parameters that allow quick risk stratification... - Cisplatin-based chemotherapy for pulmonary metastasized germ cell tumors of the testis--be aware of acute respiratory distress syndromeStefan Boeck
Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
Onkologie 32:125-8. 2009..In patients with lung metastases and a high tumor load, an association between induction chemotherapy and the development of a 'tumorassociated' acute respiratory distress syndrome (ARDS) has been hypothesized... - Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic AcidAndreas Hausmann
Medical Department III, Ludwig Maximilians University of Munich, Campus Großhadern, 81377 Munich, Germany
Chemother Res Pract 2012:858590. 2012..Conclusion. ZA was generally well tolerated; it increases BMD and reduces Dpd excretion significantly in patients with bone loss after allo-HSCT...